Applications received for new investments since 1 November 2008
|
|
|
- Sandra Shepherd
- 5 years ago
- Views:
Transcription
1 Applications received for new investments since 1 November 2008 Details of Funding Applications received are published on PHARMAC s website, in accordance with the Terms of Reference for the Pharmacology and Therapeutics Advisory Committee (PTAC) and PTAC Subcommittees Applications Received Since November 2008 Chemical (Trade) names Indication Applicant Date Received Varenicline (Champix) Smoking cessation Pfizer 5/12/2008 Erlotinib (Tarceva) Non small-cell lung cancer Astra Zeneca 5/12/2008 Losartan Review of Special Authority criteria for congestive heart failure or hypertension AstraZeneca 8/12/2008 Gefitinib (Iressa) Non small-cell lung cancer AstraZeneca 8/12/2008 Rosuvastatin (Crestor) Hyperlipdaemia AstraZeneca 9/12/2008 Etanercept (Enbrel) Severe chronic plaque psoriasis Wyeth 9/12/2008 Palivizumab (Syngagis) Respiratory syncytial virus Waikato DHB 9/12/2008 Cyclosporin Amendment of SA for steroid resistant nephrotic syndrome Individual 9/12/2008 Travoprost/timolol (Duotrav) Glaucoma Alcon 5/12/2008 Deferiprone (Ferriprox) Iron overload in thalassaemia major patients Orphan 9/12/2008 Gluten free foods Amendment to SA biopsy requirement Individual 9/12/2008 Folic Acid Prevention of neural tube defects Ministry of Health 9/12/2008
2 Gemcitabine (Gemzar) Pancreatic cancer New Zealand Association of Cancer Specialists 11/12/2008 Paliperidone (Invega) Schizophrenia Janssen-Cilag 11/03/2009 Olanzapine (Zyprexa Adhera) Schizophrenia Eli Lilly 6/03/2009 Buprenorphine (Norspan) Moderate to severe pain Mundipharma 9/03/2009 Sitagliptin (Januvia) Type 2 diabetes mellitus Merck Sharp & Dohme 20/04/2009 Sitagliptin and metformin (Janumet) Type 2 diabetes mellitus Merck Sharp & Dohme 20/04/2009 Riluzole (Rilutek) Amyotrophic lateral sclerosis Sanofi-Aventis 28/05/2009 Sorafenib (Nexavar) Hepatocellular carcinoma Bayer 8/06/2009 Thalidomide (Thalidomide Pharmion) Multiple Myeloma Celgene 11/06/2009 Budesonide (Entocort) Chron s disease New Zealand Society of Gastroenterology 11/06/2009 Lenalidomide (Revlimid) Multiple Myeloma Celgene 12/06/2009 Vildagliptin (Galvus) Type 2 diabetes mellitus Novartis 12/06/2009 Aliskirin (Rasilez) Hypertension Novartis 16/06/2009 Cox-2 inhibitors Pain New Zealand Haemophilia Treaters Group 16/06/2009 Ambrisentan (Volibris) Pulmonary arterial hypertension Glaxo 17/06/2009
3 Insulin glulisine (Apidra) Type 1 and 2 diabetes Sanofi Aventis 15/06/2009 Gluten free multi-seed bread mix Gluten intolerance Bakels 1/07/2009 Etravirine (Intelence) Antiretroviral for HIV Janssen-Cilag 03/09/2009 Rivaroxaban (Xarelto) Venous thromboembolism prophylaxis. Bayer 09/09/2009 Budesonide/eformoterol (Symbicort Turbuhaler) Asthma AstraZeneca 15/09/2009 Sunitinib (Sutent) Advanced renal cell carcinoma Pfizer 15/09/2009 Gemcitabine (Gemzar) Pancreatic cancer Gastrointestinal Cancer Special Interest Group of the New Zealand Association of Cancer Specialists 15/09/2009 Dornase alpha Cystic fibrosis Individual 15/09/2009 Milk substitute formula (S-26 Gold premgro) Premature infants Wyeth 19/10/2009 Gemcitabine Cholangiocarcinoma Gastro-Intestinal Special Interest Group 21/10/2009 Naltrexone Alcohol addiction Individuals 30/10/2009 Docetaxel Early breast cancer New Zealand Breast Cancer Special Interest Group 11/11/2009 Oral supplementary food (Enprocal) Malnutrition and physical frailty Warrnambool 03/12/2009 Bevacizumab (Avastin) Metastatic colorectal cancer Roche 07/12/2009
4 Imiquimod (Aldara) Actinic keratosis. Douglas 07/12/2009 Multiple sclerosis treatments Multiple sclerosis Individual 07/12/2009 Bortezomib (Velcade) Multiple myeloma. Janssen-Cilag 07/12/2009 Prasugrel (Effient) Acute coronary syndromes Eli Lilly 08/12/2009 Isopropyl alcohol and anhydrous glycerine (Ear clear) Prevention of swimmers ear Key Pharmaceuticals 08/12/2009 Losartan (Cozaar, Hyzaar) Gout Ngā Kaitiaki o Te Puna Rongoā o Aotearoa 30/12/2009 Levofloxacin Helicobacter pylori Clinician 16/02/2010 Tenofovir/emtricitabine (Truvada) HIV Gilead 26/02/2010 Tenofovir/emtricitabine/efavirenz (Atripla) HIV Gilead 26/02/2010 Teriparatide (Forteo) Osteoporosis Eli Lilly 01/03/2010 Sildenafil (Viagra) Persistent pulmonary hypertension of the newborn with associated lung disease; congenital diaphragmatic hernia; chronic neonatal lung disease Clinician 04/03/2010 Rituximab (Mabthera) Chronic lymphocytic leukaemia Roche 8/03/2010 Metronidazole (Zidoval Gel) Bacterial vaginosis Douglas Pharmaceuticals Limited 8/03/2010 Vitamin D (OsteoVit-D) Vitamin D deficiency Wilson Consumer Products 9/03/2010
5 Vitamin D and calcium (OsteoVit-D & Calcium) Golimumab (Simponi) Vitamin D deficiency and osteoporosis Wilson Consumer Products 9/03/2010 Rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis Merck Sharpe and Dohme 09/03/2010 Darunavir (Prezista) HIV Janssen-Cilag 9/03/2010 Levonorgestrel micronizado (Jadelle) Long-acting contraception Bayer 09/03/2010 Sildenafil Pulmonary arterial hypertension Individual 12/04/2010 Hydrolysed rice protein formula (Risolac) Food allergies Heinz Watties 21/04/2010 Oral nutritional feed (Fortisip compact) Malnutrition Nutricia 23/04/2010 Paediatric oral feed (Infatrini) Paediatric oral feed (Nutrini Energy Multi Fibre) Paediatric oral feed (Nutrini Low Energy Multi Fibre) Infants with increased nutritional requirements Nutricia 23/04/2010 Disease related malnutrition Nutricia 23/04/2010 Enteral nutritional support Nutricia 23/04/2010 Oral nutritional supplement (Fortijuce) Malnutrition Nutricia 23/04/2010 Paediatric oral feed (Neocate Nutra) Food allergies Nutricia 23/04/2010 Ketogenic supplement (KetoCal) Chronic intractable epilepsy Nutricia 23/04/2010 Oral nutritional supplement (PKU Anamix Junior LQ) Phenylketonuria Nutricia 23/04/2010 Elemental formula (Alfara) Gastrointestinal and other malabsorptive problems Nestle Nutrition 04/05/2010
6 Bortezomib Multiple myeloma Individual 5/05/2010 Naltrexone Henoch-schonlein purpura Individual 26/03/2010 Pipobroman Polycythemia rubra vera and essential thrombocythaemia Individual 31/03/2010 Multiple Sclerosis Treatments Multiple Sclerosis Individual 12/04/2010 Prasugrel (Effient) Acute coronary syndromes Eli Lilly 3/05/2010 Paliperidone (Invega) Schizophrenia Janssen-Cilag 17/05/2010 Azacitidine (Vidaza) Myelodysplastic syndrome Celgene 18/05/2010 Lacosamide (Vimpat) Epilepsy UCB 21/05/2010 Deferasirox (Exjade) Iron overload Novartis 25/05/2010 Quetiapine extended release (Seroquel XR) Schizophrenia AstraZeneca 25/05/2010 Riluzole (Rilutek) Amyotrophic lateral sclerosis Sanofi Aventis 25/05/2010 Sitagliptin/metformin (Januvia/Janumet) Diabetes Merck Sharp & Dohme 25/05/2010 Dabigatran (Pradaxa) Stroke, systemic embolism, atrial fibrillation Boehringer Ingelheim 25/05/2010 Varenicline (Champix) Smoking cessation Pfizer 25/05/2010 Deferiprone (Ferriprox) Iron overload Orphan 21/06/2010
7 Imiglucerase Gaucher s disease Individual 6/07/2010 Bortezomib AL amyloidosis Individual 16/07/2010 Lapatinib HER 2 positive metastatic breast cancer New Zealand Breast Cancer Special Interest Group 21/07/2010 Rifabutin H. Pylori Individual 27/07/2010 Paracetamol and ibuprofen (Maxigesic) Analgesia and fever reduction AFT Pharmaceuticals 4/08/2010 Miglustat (Zavesca) Type 1 Gaucher s disease Actelion 17/08/2010 Fluticasone propionate / salmeterol xinafoate (Seretide) Asthma Glaxo Smith Kline 17/08/2010 Adalimumab (Humira) Juvenile idiopathic arthritis Abbott 17/08/2010 Posaconazole (Noxafil) Aspergillus Merck Sharp & Dohme 17/08/2010 Nab-paclitaxel (Abraxane) Advanced breast cancer Specialised Therapeutics 17/08/2010 Ivermectin Crusted scabies Individual 19/09/2010 Clodronate (Ostac) Osteoradionecrosis Individual 19/10/2010 Mycophenolate Severe atopic eczema Individual 17/11/2010 Pazopanib (Votrient) Advanced and/or metastatic renal cell carcinoma GlaxoSmithKline 23/11/2010 Trastuzumab (Herceptin) Metastatic HER2 positive gastric cancer Roche 26/11/2010
8 Lapatinib (Tykerb) HER2 positive metastatic breast cancer GlaxoSmithKline 29/11/2010 Docetaxel Metastatic castration resistant prostate cancer Individual 19/11/2010 Mycophenolate Lupus nephritis Individual 29/11/2010 Tiotropium bromide (Spiriva) Chronic obstructive pulmonary disease Boehringer Ingelheim 30/11/2010 Nilotinib (Tasigna) Chronic myeloid leukaemia Novartis 22/12/2010 Olanzapine (Olanzaccord) Psychoses Airflow Products 22/01/2011 Bortezomib Dabigatran (Pradaxa) Levonorgestrel (Mirena) Testosterone undecanoate (Reandron 1000) First line multiple myeloma with cast nephropathy Stroke, systemic embolism, atrial fibrillation Contraception Clinician 26/01/2011 Boehringer Ingelheim 03/02/2011 Royal Australian and New Zealand College of Obstetricians and Gynaecologists 17/02/2011 Testosterone replacement Bayer 22/02/2011 Ustekinumab (Stelara) Psoriasis Janssen-Cilag 22/02/2011 Rituximab (Mabthera) Cevimeline Relapsed/refractory follicular non- Hodgkin s lymphoma Dry mouth (including Sjogren s syndrome) Roche 22/02/2011 Sjogren s Syndrome Society of NZ Inc. 1/03/2011 Valganciclovir Cytomegalovirus Haematology Society 30/05/2011
9 Fluticasone/salmeterol Asthma Individual 30/05/2011 Pregabalin (Lyrica) Neuropathic pain Pfizer 31/05/2011 Sorafenib (Nexavar) Hepatocellular carcinoma (HCC) and advanced renal cell carcinoma (RCC) Bayer New Zealand Ltd 30/08/2011 Everolimus (Afinitor) Advanced renal cell carcinoma (RCC) Novartis New Zealand Ltd 30/08/2011 Sunitinib (Sutent) Gastrointestinal stromal tumour (GIST) Pfizer 30/08/2011 Gefitinib (Iressa) Locally advanced or metastatic non small cell lung cancer (NSCLC) AstraZeneca 30/08/2011 Ticagrelor (Brilinta) Acute coronary syndromes AstraZeneca 30/08/2011 Tiotropium Bromide (Spiriva) Ammendment to SA for chronic obstructive pulmonary disease Boehringer Ingleheim 30/08/2011 Adalimumab (Humira) Crohn s disease Abbott Laboratories NZ 30/08/2011 Saxagliptin (Onglyza) Type II diabetes AstraZeneca 30/08/2011 Tocilizumab (Actemra) Rheumatoid arthritis (RA) and systemic juvenile idiopathic arthritis (sjia) Roche Products (New Zealand) Ltd 30/08/2011 Indacaterol (ONBREZ inhaler) Chronic obstructive pulmonary disease Novartis 22/11/2011 Cetolizumab (Cimzia) Rheumatoid arthritis UCB 22/11/2011 Dutasteride (Avodart) Benign prostatic hyperplasia GlaxoSmithKline 22/11/2011 Eculizumab (Solaris) Paroxysmal nocturnal haemaglobinuria Alexion Pharmaceuaticals 22/11/2011
10 Vemurafenib (Zelboraf) Eltrombopag (Revolade) Erlotinib (Tarceva) Stage IIIC/IV melanoma BRAF V600 mutation Idiopathic Thrombocytoponic Purpura (ITP) Non-small cell lung cancer with EGFR activating mutation Roche 22/11/2011 GlaxoSmithKline 22/11/2011 Roche 22/11/2011 Fingolimod (Gilenya) Multiple Sclerosis Novartis 22/11/2011 Telaprevir (Incivo) Hepatitis C Janssen-Cliag Pty Ltd 22/11/2011 Azithromycin Pertussis and Neonatal Ophthalmia Paediatric Society of NZ 24/02/2012 Boceprevir (Victrelis) Hepatitis C MSD 28/02/2012 Capsaicin Tropical Cream (Zostrix) Osteoarthritis AFT Pharmaceuticals 25/01/2012 Denosumab (Prolia) Postmenopausal Osteoporosis Amgen 28/02/2012 Gemcitabine Metastatic Breast Cancer New Zealand Breast Cancer Special Interest Group 01/02/2012 Natalizumab (Tysabri) Multiple Sclerosis Biogen 28/02/2012 Liraglutide (Victoza) Type II Diabetes Novo Nordisk 28/02/2012 Temozolomide (Temodal) Testosterone Undecanoate (Reandron) Widen access for oligondendroglial tumours Clinician s Application 21/02/2012 Testosterone Deficiency Bayer Health Care 28/02/2012 Progesterone (Utrogestan) Unwanted symptoms of menopause Pharmaco 02/04/2012
11 TNF Inhibitors Rituximab Oxaliplatin and Irinotecan (Folfoxiri) Behcet s Disease ANCA associated vasculitis and polyarteritis nodosa Metastatic Pancreas Adenocarcinoma New Zealand Rheumatology Association New Zealand Rheumatology Association Gastrointestinal Cancer Special Interest Group of NZACS 26/04/ /05/ /05/2012 Asenapine (SAPHRIS) Schizophrenia and Bipolar 1 disorder Lundbeck 15/05/2012 Rivaroxaban (Xarelto) Rivaroxaban (Xarelto) Ipilimumab (Yervoy) Bovine Lipid Extract Surfactant (BLES) Sodium Hyaluronate Eye Drops (Hylo- Fresh and Hylo-Forte) Tenofovir Disoproxil Fumarate (Viread) Rituximab Stroke prevention in atrial fibrillation (SPAF) Treatment of DVT and prevention of recurrent DVT and PE Previously treated unresectable stage IIIc or IV melanoma Bayer Health Care 21/05/2012 Bayer Health Care 21/05/2012 Bristol-Myers Squibb 21/05/2012 Neonatal Respiratory Distress Syndrome Rex Medical 01/08/2012 Dry eyes AFT Pharmaceuticals 27/08/2012 Hepatitis B with advanced fibrosis/cirrhosis Refractory Systemic Lupus Erythematosus (SLE) Gilead Sciences 27/08/2012 New Zealand Rheumatology Association 06/06/2012 Rituximab 17p Chronic Lymphocytic Leukaemia Clinician s Application 24/08/2012 Pegylated-Asparaginase Acute Lymphoblastic Leukaemia Clinician s Application 12/06/2012 Nilotinib Chronic Myeloid Leukaemia Haematology Society 02/08/2012 Infliximab Juvenile Idiopathic Arthritis with chronic anterior uveitis New Zealand Paediatric Rheumatology Service 02/08/2012
12 Ferric Carboxymaltose (Ferinject) Iron Deficiency Anaemia Vifor Pharma 27/08/2012 Saxagliptin (Onglyza) Type 2 Diabetes with renal impairment Astra Zeneca 28/08/2012 Melatonin (Circadin) Insomnia Aspen Pharma 28/08/2012 Carbetocin (Duratocin) Sevelamer (Renagel) Uterine Atony and excessive bleeding following elective caesarean under epidural or spinal anaesthesia Hyperphosphataemia in adult patients with chronic kidney disease on dialysis Pharmaco 01/10/2012 Sanofi 26/11/2012 Rilpivirine (Edurant) HIV/AIDS Janssen-Cilag 27/11/2012 Bortezomib (Velcade) Multiple Myeloma Janssen-Clag 27/11/2012 Everolimus Sub-ependymal giant cell astrocytoma not amenable to neurosurgical resection Clinician 29/11/2012 Long-Acting Ocreotide Metastatic or Unresectable SI-NET s Clinician 19/09/2012 Renal Multivtamins Renal Disease Douglas Pharmaceuticals 27/11/2012
Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December
Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December 17 2010. 32/10 Imatinib for gastrointestinal stromal tumours (unresectable/metastatic) (update on
NICE TA Adherence Check List
NICE TA Adherence Check List KEY NICE TA PAS Not Terminated Indication Technology Appraisal carried out by the National Institute of Clinical Excellence - It is the process by which new and existing drugs
Funding Medicines in New Zealand: Revision of the Medicines Waiting List
Funding Medicines in New Zealand: Revision of the Medicines Waiting List Author: Cristine Della Barca February 2016 Page 1 of 12 Funding Medicines in New Zealand: Revision of the Medicines Waiting List
2014 DTC National Advertising Awards Finalists
2014 DTC National Advertising Awards Finalists All Gold, Silver, and Bronze winners will be announced at the DTC National Advertising Awards Dinner on April 23. Each therapeutic category winner from Television,
Azacitidine Vidaza Non-transplant myelodysplastic syndrome Funded Funded Funded Funded Funded Funded Not Funded
Provincial Fundin Summary The interim Joint Oncoloy Dru Review (ijodr) was the precursor oncoloy dru review process prior to pcodr, which provided evidence-based recommendation for cancer treatments from
PBS Growth. The changing composition of the PBS. PBS Top 10 drugs in transition. Shifting sands for industry as generic volume soars
PBS Growth The changing composition of the PBS PBS Top 10 drugs in transition Shifting sands for industry as generic volume soars The under co-payment market PBS Update 2014-15 Growth in PBS spending was
HEALTH MATTERS, INC. SUMMARY OF PROJECTS AND KEY ACCOMPLISHMENTS TO 2016
Selected 2016 Highlights Epidemiologic research on chronic kidney disease and fistula patency, solid and hematologic malignancies Health economics and outcomes research on beta3-agonist treatment for overactive
Funding Medicines in New Zealand: Revision of the Medicines Waiting List
Funding Medicines in New Zealand: Revision of the Medicines Waiting List Author: Cristine Della Barca February 2017 Page 1 of 12 Funding Medicines in New Zealand: Update of the Medicines Waiting List Executive
Proposal to fund a number of Nutritional products (Special Foods) supplied by Nutricia
16 February 2012 Proposal to fund a number of Nutritional products (Special Foods) supplied by Nutricia PHARMAC is seeking feedback on a proposal to fund a number of nutritional products (Special Foods)
The Royal Marsden NHS Foundation Trust Medicines Formulary. NICE register for medicines initiated at the trust. Type and code. Publication.
NICE register for medicines initiated at the trust. CG denotes Clinical Guideline TA denotes Technical Appraisal For further information about NICE and full guidelines please refer to www.nice.org.uk Title
Funding Medicines in New Zealand: Revision of the Medicines Waiting List to 30 June 2018
Funding Medicines in Zealand: Revision of the Medicines Waiting List to 30 June 2018 Author: Cristine Della Barca July 2018 Page 1 of 16 Funding Medicines in Zealand: Update of the Medicines Waiting List
New Mexico Health Connections Drug Safety Updates. Drug Safety Updates Q Route of Administration. Action. Brand Name Generic Name Indications
Q4 2017 Advair Diskus salmeterol Asthma, COPD inhaler Advair HFA salmeterol Asthma inhaler Airduo Respiclick salmeterol Asthma inhaler Alecensa alectinib Non-Small Cell Lung Cancer Genentech announced
Appraisals. What is a NICE Technology Appraisal? Logo Here
Add A view your from Presentation NICE: Technology Title Here.. Appraisals Add Helen your Knight, name 9 and May organisation 2013 Logo Here What is a NICE Technology Appraisal? A review of clinical and
National Cancer Drugs Fund List - Approved
National Cancer Drugs Fund List - Approved DRUG Abiraterone Aflibercet Albumin Bound Paclitaxel Axitinib CDF INDICATION (EXCLUDING APPROVED CRITERIA ) Metastatic Prostate Cancer Metastatic Colorectal Cancer
Manufacturing and Marketing permission issued from SND Division from to
Manufacturing and Marketing permission issued from SND Division from 01.01.2018 to 31.05.2018. S.No Drug Name Composition Indication Date of Approval As a component of multi agent Pegaspargase Each vial
April May For adults for the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion.
April May 2014 Recommended for use within NHS Scotland April May 2014 aflibercept intravitreal (Eylea ) 954/14 For adults for the treatment of visual impairment due to macular oedema secondary to central
Senate Community Affairs Committee ANSWERS TO ESTIMATES QUESTIONS ON NOTICE HEALTH PORTFOLIO
Senate Community Affairs Committee ANSWERS TO ESTIMATES QUESTIONS ON NOTICE HEALTH PORTFOLIO Supplementary Budget Estimates 2018-2019, 24 October 2018 Ref No: SQ18-001266 OUTCOME: 4 - Individual Health
Immune Modulating Drugs Prior Authorization Request Form
Patient: HPHC member ID #: Requesting provider: Phone: Servicing provider: Diagnosis: Contact for questions (name and phone #): Projected start and end date for requested Requesting provider NPI: Fax:
Changes in Benefit Status and Criteria Update: Topiramate
JANUARY 2016 Nova Scotia Formulary Updates Changes in Benefit Status and Criteria Update Topiramate Change in Benefit Status Escitalopram Criteria Update Actemra Januvia and Janumet Cimzia New Product
Cancer Treatments Subcommittee of PTAC meeting held 20 August. (minutes for web publishing)
Cancer Treatments Subcommittee of PTAC meeting held 20 August 2010 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology
Nutritional products (Special Foods) supplied by Nutricia
2 April 2012 Nutritional products (Special Foods) supplied by Nutricia PHARMAC is pleased to announce the funding of a number of nutritional products (Special Foods) supplied by Nutricia. These products
List of Recombinant DNA based Drugs Approved in the Country (Form-45) 1st Jan st Dec 2013
S.No. 1 Name of the firm Ferring Date of Approval 4-Apr-10 License No. Import-450/10 2 G.C.Chemie 23-Jun-10 IMP-572/10 3 R.K. Medicare 9-Sep-10 IMP-783/10 4 5 List of Recombinant DNA based Drugs Approved
NICE TA Adherence Check list April Drug Indication NICE Approval Release Date
NICE TA Adherence Check list April 2014 Drug Indication NICE Approval Release Date Bortezomib Multiple myeloma (induction therapy) Afatinib Rituximab Pixantrone Aflibercept Teriflunomide Fluocinolone acetonide
WITBANK COALFIELDS MEDICAL AID SCHEME (WCMAS) CHRONIC MEDICINE PROGRAMME GENERAL INFORMATION LETTER
WITBANK COALFIELDS MEDICAL AID SCHEME (WCMAS) CHRONIC MEDICINE PROGRAMME GENERAL INFORMATION LETTER The Prescribed Minimum Benefit Chronic Disease List In terms of the Medical Scheme Act Regulations that
29 August 2016 Page 1 of 7. How does the NHS board decide which new medicines to make available for patients?
NHS Greater Glasgow and Clyde: New Medicines Decisions In Scotland, a newly licensed medicine is routinely available for use in an NHS board only after it has been: accepted for use in the NHSScotland
Drug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases
Drug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases Line of Business: Medicaid P & T Approval Date: August 16, 2017 Effective Date: August 16, 2017 This policy
Dr Daniel Ching. Rheumatology Therapeutic Clinical Trials Centre Timaru
Dr Daniel Ching Rheumatology Therapeutic Clinical Trials Centre Timaru Therapeutic Advances in Rheumatology GP CME Meeting, Dunedin, 18.08.2013 Dr Daniel Ching, MB FRCP FRACP Consultant Rheumatologist,
CHRONIC MEDICINE PROGRAMME GENERAL INFORMATION LETTER
RAND WATER MEDICAL SCHEME RAND WATER MEDICAL SCHEME CHRONIC MEDICINE PROGRAMME GENERAL INFORMATION LETTER LIST OF CHRONIC CONDITIONS Conditions covered under s chronic medication benefit are detailed below.
GASTRIC CANCER TESTING, TREATMENT AND PREVENTION: TECHNOLOGIES AND GLOBAL MARKETS. HLC174A October Usha Nagavarapu Project Analyst
GASTRIC CANCER TESTING, TREATMENT AND PREVENTION: TECHNOLOGIES AND GLOBAL MARKETS HLC174A October 2015 Usha Nagavarapu Project Analyst ISBN: 1-62296-167-6 BCC Research 49 Walnut Park, Building 2 Wellesley,
PHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA JULY 2013 PBAC MEETING. Closing date for consumer comments 12 June 2013
The PBAC agenda primarily consists of applications relating to the new listing of a drug or vaccine on the PBS or the National Immunisation Program. The PBAC agenda consists of the following: 1 Minutes
CHRONIC TREATMENT GUIDELINES
CHRONIC TREATMENT GUIDELINES REGISTRATION OF CHRONIC CONDITIONS You can only access benefits for chronic medication, as listed below, if your prescribing/treating doctor or pharmacist registers your chronic
Medication Policy Manual. Topic: Otezla, apremilast Date of Origin: May 9, 2014
Medication Policy Manual Policy No: dru342 Topic: Otezla, apremilast Date of Origin: May 9, 2014 Committee Approval Date: January 19, 2015 Next Review Date: January 2016 Effective Date: April 1, 2015 IMPORTANT
Area Drug and Therapeutics Committee Prescribing Supplement No 22 June 2008
Area Drug and Therapeutics Committee Prescribing Supplement No 22 In this issue Drugs currently being considered by SMC advice due on 09 ADTC decisions carried over from the previous bulletin in February
CUMULATIVE ILLNESS RATING SCALE (CIRS)
CUMULATIVE ILLNESS RATING SCALE (CIRS) The CIRS used in this protocol is designed to provide an assessment of recurrent or ongoing chronic comorbid conditions, classified by 14 organ systems. Using the
Manufacturing and Marketing permission issued from SND Division from to
Manufacturing and Marketing permission issued from SND Division from 01.01.2018 to 04.07.2018. S.No Drug Name Composition Indication Date of Approval As a component of multi agent Pegaspargase Each vial
Opening Address: A Quick Survey Thinking 25 Years Backwards & Forwards
Opening Address: A Quick Survey Thinking 25 Years Backwards & Forwards Jeffrey M. Bockman, PhD Vice President Defined Health 24 th Annual Cancer Progress Conference March 4 th 5 th, 2014 March 4 th 5 th,
Volume 10; Number 4 February 2016
Arden and Greater East Midlands Commissioning Support Unit in association with Lincolnshire Clinical Commissioning Groups, Lincolnshire Community Health Services, United Lincolnshire Hospitals Trust and
ICON Formulary - October 2018 Legend - ICON Protocols Essential (previously Standard), Core, Enhanced Core, Enhanced Enhanced
ICON Formulary - October 2018 Legend - ICON Protocols Essential (previously Standard), Core, Enhanced Core, Enhanced Enhanced Class Medicine Name Nappi Strength Form Size Route Abiraterone Acetate ZYTIGA
NATIVA GROUP. Inspired by Innovation and Technology
NATIVA GROUP Inspired by Innovation and Technology INNOVATION & TECHNOLOGY IS OUR PASSION Nativa is a leading group of pharmaceutical companies in Russia. It develops and produces worldclass complex medicines
A 10-year summary of kinase small molecule research Text mining AACR abstracts (white paper)
A 10-year summary of kinase small molecule research Text mining AACR abstracts (white paper) Approved Kinase Inhibitors September 2014 Sponsored by PamGene www.pamgene.com The Kinase Activity Profiling
Review of predictive biomarkers in European Medicines Agency (EMA) drugs
Review of predictive biomarkers in European Medicines Agency (EMA) drugs Kinga Malottki, Mousumi Biswas, Jon Deeks, Richard Riley, Charles Craddock, Lucinda Billingham 10 February 2012 Objectives What
Proposal relating to the funding of TNF inhibitors (Humira and Enbrel) and gabapentin (Neurontin)
14 July 2015 Proposal relating to the funding of TNF inhibitors (Humira and Enbrel) and gabapentin (Neurontin) PHARMAC is seeking feedback on a proposal relating to the funding of the TNF-inhibitor medicines
Drug Class Review Targeted Immune Modulators
Drug Class Review Targeted Immune Modulators Final Update 5 Report June 2016 The purpose of reports is to make available information regarding the comparative clinical effectiveness and harms of different
List of Qualifying Conditions
List of Qualifying Conditions Cancer Conditions 1) Adrenal cancer 2) Bladder cancer 3) Bone cancer all forms 4) Brain cancer 5) Breast cancer 6) Cervical cancer 7) Colon cancer 8) Colorectal cancer 9)
10 Musculoskeletal and Joint Diseases
Recommendations from the Lothian Formulary Committee (FC) following Scottish Medicines Consortium (SMC) advice, NICE MTA advice, (FAF3) unlicensed and off-label medicines and (FAF2) medicines not considered
University of Groningen. Health economics of targeted cancer therapies Mihajlovic, Jovan
University of Groningen Health economics of targeted therapies Mihajlovic, Jovan IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please
Clinical Research Institute HUCH Sponsored, fully signed Clinical Trial Agreements (except grants)
, fully signed Clinical Trial Agreements (except grants) Sponsor Full name of the Hospital clinic where the is details of the January x x January x NightstaRx Ltd A Randomised, Open Label, Outcomes-Assessor
Vectibix (panitumumab) will be considered medically necessary when all of the following criteria are met:
What s New Medical Pharmaceutical Policy November 2017 Updates MBP 40.0 Orencia IV (abatacept)- New Indication Orencia IV (abatacept) will be considered medically necessary when all of the following criteria
Corporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: infliximab_remicade 5/2002 2/2017 2/2018 2/2017 Description of Procedure or Service Infliximab (REMICADE
MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization
MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Anticoagulants A. Prescriptions That Require Prior Authorization Prescriptions for Anticoagulants
04 September 2017 Page 1 of 6
NHS Greater Glasgow and Clyde: New Medicines Decisions In Scotland, a newly licensed medicine is routinely available in a health board only after it has been: accepted for use in by the Scottish Medicines
Prior treatment with non-biologic Disease- Modifying Antirheumatic. Not to be used in combination with another biologic DMARD
Abatacept (Orencia) 1, 2, 7, 11, 13, 14, 18, 24, 31, 44, 48, 49, 51, 53, 55, 57 J0129 Alpha 1 - Proteinase inhibitor (Prolastin-C) 5, 6, 10, 12, 40 Medically Necessary (if all the following criteria apply):
Directorate General of Health Services Office of Drugs Controller General (India) (Biological Division)
Directorate General of Health Services Office of Drugs Controller General (India) (Biological Division) List of r-dna drug products approved in the country (Form 45 and 45A) from 1 st Jan 2015 to 30 th
Compassionate use programma's die zijn goedgekeurd door het CBG Laatst bijgewerkt op: 21 juni 2018
Compassionate use programma's die zijn goedgekeurd door het CBG Laatst bijgewerkt op: 21 juni 2018 Het CBG kan in schrijnende gevallen toestemming verlenen voor het in de handel brengen van een geneesmiddel
2014 Date of Guidance Title of Guidance Summary of Recommendations Ratified at Croydon Time to Publication Number Prescribing Committee
NICE Technology Appraisals - Time to Implementation Report - 18 December 2014 Produced by Tracy Steadman, Croydon Public Health Intelligence Team (C-PHIT), Croydon Council Date of Guidance Title of Guidance
Clinical Therapeutic Intelligence Report: Year in Review
Clinical Therapeutic Intelligence Report: Year in Review Last year marked a productive year for oncology drug research and development with ten new oncology drugs coming to market two of which were granted
CIMZIA (certolizumab pegol)
Pre - PA Allowance None Prior-Approval Requirements Age Diagnoses 18 years of age or older Patient must have ONE of the following: 1. Moderate to severe Crohn s Disease (CD) a. Inadequate response, intolerance
Cimzia. Cimzia (certolizumab pegol) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.11 Section: Prescription Drugs Effective Date: April 1, 2018 Subject: Cimzia Page: 1 of 5 Last Review
Step Therapy Approval Criteria
Effective Date: 10/01/2016 This document contains Step Therapy Approval Criteria for the following medications: 1. Colcrys (colchicine) 2. Cymbalta (duloxetine) 3. Dovonex (calcipotriene) 4. Enbrel (etanercept)
Target date to recruit patients agreed? Target range minimum. Target range maximum. Agreed 1 1 Agreed 01/01/ /01/2016 Recruitment Finished
No REC Reference IRAS No Title Target number of patients agreed? Target range minimum Target range maximum Target date to recruit patients agreed? Planned Recruitment end date No of patients recruited
CHRONIC MEDICATION PROGRAMME INCLUDES PRESCRIBED MINIMUM BENEFIT CHRONIC DISEASE LIST (CDL)
CHRONIC MEDICATION PROGRAMME INCLUDES PRESCRIBED MINIMUM BENEFIT CHRONIC DISEASE LIST (CDL) A. GENERAL INFORMATION LIST OF CHRONIC CONDITIONS Conditions covered under KeyHealth s chronic medication benefit
NEW MEDICINE APPLICATIONS BROUGHT TO THE BORDERS FORMULARY COMMITTEE (BFC) AND AREA DRUG & THERAPEUTICS COMMITTEE (ADTC) 2015/16
New Medicine Product/Device Endorsement Categories NEW MEDICINE APPLICATIONS BROUGHT TO THE BORDERS FORMULARY COMMITTEE (BFC) AND AREA DRUG & THERAPEUTICS COMMITTEE (ADTC) 2015/16 A B C D E F recommended
Lincolnshire Prescribing and Clinical Effectiveness Bulletin
S Lincolnshire Prescribing and Clinical Effectiveness Bulletin Volume 11 No 12, September 2017 Optum in association with Lincolnshire Clinical Commissioning Groups, Lincolnshire Community Health Services,
INFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Ixifi* (infliximabqbtx), Renflexis (infliximab-abda)
Pre - PA Allowance None Prior-Approval Requirements Diagnoses Patient must have ONE of the following: 6 years of age or older 1. Moderate to severe Crohn s disease (CD) a. Patient has fistulizing disease
Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine TA440
This spreadsheet is updated monthly and enables self-audit of a medicines for All guidelines refer to adults unless indicated. No copyright is asserted on this Technology appraisal (TA) Titles are hyperlinks
LECOM Health Ophthalmology
Patient Name: Date of Birth: New Patient Questionnaire Your answers will be used by your healthcare provider get an accurate history of your medical conditions and ocular concerns. If you are uncomfortable
P.E.I. Drug Programs. Formulary Update. Issue June 09, 2010
P.E.I. Drug Programs Formulary Update Issue 10-01 June 09, 2010 st Effective July 1, 2010, the following medications will be added to the P.E.I. Drug Formulary. New medications for the treatment of ankylosing
Biologics for Autoimmune Diseases
Biologics for Autoimmune Diseases Goal(s): Restrict use of biologics to OHP funded conditions and according to OHP guidelines for use. Promote use that is consistent with national clinical practice guidelines
July 2014 PBAC OUTCOMES - "1 st time" decisions not to recommend. Drug Type and Use. Drug Name, form(s), strength(s), Sponsor,
July 2014 PBAC OUTCOMES - "1 st time" decisions not to recommend Drug Name, form(s), ABIRATERONE, tablet, 250 mg, Zytiga Janssen-Cilag Pty Ltd Change to listing Prostate Cancer Section 85 Authority required
Summary of Strategic Competitive Analysis and Publication Planning
Summary of Strategic Competitive Analysis and Publication Planning Carole Alison Chrvala, PhD 919.545.2149 (Work) 919.951.5230 (Mobile) cchrvala@centurylink.net www.healthmattersmedwriting.com 1 Briefing
PROFMED MEDICAL SCHEME CHRONIC MEDICINE BENEFIT GENERAL INFORMATION
PROFMED MEDICAL SCHEME CHRONIC MEDICINE BENEFIT GENERAL INFORMATION The Prescribed Minimum Benefit Chronic Disease List In terms of the Medical Schemes Act Regulations that came into effect on 1 January
Supplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Ruperto N, Martini A. Current and future perspectives
EVIDENCE-BASED VITAMIN AND MINERAL USAGE SUMMARY TABLE (APRIL 2002)
Acne Acrodermatitis Enteropathica Adrenal Support Age Related Cognitive Decline Alcoholism/Alcohol Withdrawal Alzheimer's Disease Amenorrhoea Anaemia Angina Anorexia Nervosa Anxiety Asthma Atherosclerosis
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP)
22 July 2011 EMA/CHMP/557552/2011 corr* 1 Press Office Press release Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 July 2011 Positive opinions for new medicines
Spring How will that pipeline drug impact my benefit plan?
Spring 2012 How will that pipeline drug impact my benefit plan? How will that pipeline drug impact my benefit plan? It can be difficult to predict the impact pipeline drugs will have once they reach the
PTAC meeting held 4 & 5 November (minutes for web publishing)
PTAC meeting held 4 & 5 November 2010 (minutes for web publishing) PTAC minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics Advisory Committee (PTAC) and
Pfizer Pipeline. August 9, 2012
Pfizer Pipeline August 9, 2012 Disclaimer As some programs are still confidential, some candidates may not be identified in this list. In these materials, Pfizer discloses Mechanism of Action (MOA) information
PEI Drug Programs. Issue February 20, 2009
PEI Drug Programs Formulary Update Issue 09-01 February 20, 2009 New medications for the treatment of cancer, chronic obstructive pulmonary disease (COPD), osteoporosis, and HIV/AIDS have been approved
Medicare Part C Medical Coverage Policy
Step Therapy: Part B Medications Origination: December 19, 2018 Review Date: December 19, 2018 Next Review: December 2020 Medicare Part C Medical Coverage Policy DESCRIPTION OF PROCEDURE SERVICE Step Therapy
Biologics in rheumatic diseases
Biologics in rheumatic diseases Dimitrios A. Vassilopoulos, MD Joint Rheumatology Program Clinical Immunology-Rheumatology Unit 2 nd Department of Medicine and Laboratory National and Kapodistrian University
Pharmacy and Medical Guideline Updates
STAT Bulletin PO Box 15013 Albany, New York 12212 August 2, 2010 Volume 8: Issue 19 To: All PCPs and Specialists Contracts Affected: All Lines of Business Pharmacy and ical Guideline Updates As a result
JULY 2016 PBAC MEETING POSITIVE RECOMMENDATIONS LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION
ADRENALINE I.M. injection 150 micrograms in 0.3 ml single dose syringe auto-injector I.M. injection 300 micrograms in 0.3 ml single dose syringe auto-injector Adrenaline Auto Inject Sun-JV Ranbaxy Australia
1 P a g e. Systemic Juvenile Idiopathic Arthritis (SJIA) (1.3) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis.
LENGTH OF AUTHORIZATION: Initial: 3 months for Crohn s or Ulcerative Colitis; 1 year for all other indications. Renewal: 1 year dependent upon medical records supporting response to therapy and review
Pharmacotherapy Handbook
Pharmacotherapy Handbook Eighth Edition Barbara G. Wells, PharmD, HP, FCCP, BCPP Dean and Professor Executive Director, Research Institute of Pharmaceutical Sciences School of Pharmacy, The University
Cimzia. Cimzia (certolizumab pegol) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Cimzia Page: 1 of 5 Last Review Date: March 17, 2017 Cimzia Description Cimzia (certolizumab pegol)
R&D Pipeline (November 2005)
R&D Pipeline (November 2005) 1Japan (1)Filed Code No YM905 YM177 YM152 FK463 Generic Name (Filing Date ) solifenacin (Aug 2004) celecoxib (Dec 2002) finasteride (Dec1994) micafungin (July 2004) (Oct 2005)
Respiratory Subcommittee of PTAC meeting held 5 February (minutes for web publishing)
Respiratory Subcommittee of PTAC meeting held 5 February 2010 (minutes for web publishing) Respiratory Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology
Afinitor. Afinitor and Afinitor Disperz (everolimus) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.62 Subject: Afinitor Page: 1 of 7 Last Review Date: June 22, 2017 Afinitor Description Afinitor and
IRB INDICATION Number ENROLLED
Revised 1/6/2011 OPEN TRIALS 2006-2011 INDICATION Number ENROLLED SPONSOR Title Provided Phase I AZA PH US 2007 PK 006 Celgene A Phase I, Open-Label, Multi-Center, Parallel Group Study to Assess the Pharmacokinetics
DOSSIER LIST. tlo_seledyn.pdf :38:01 CMY K CM MY CY
tlo_seledyn.pdf 1 22.08.2017 14:38:01 C M Y CM MY CY CMY K DOSSIER LIST AVAILABLE DOSSIERS THERAPEUTIC CLASS / MAIN INDICATION LACTOSE FREE ZONE IV CPP FEASIBILITY ALIMENTARY TRACT & METABOLISM 1. Esomeprazole
Mrs. Isabelle GAUDIN 22 years experience in Clinical Research LEAD CRA / SENIOR CLINICAL RESEARCH ASSOCIATE
Sté Aid ARC 36, Comba dels Martirs 11570 PALAJA FRANCE Fax : +33 4 68 47 03 52 Mob : +33 6 14 68 71 71 E-mail : isabelle.gaudin@aidarc.com Mrs. Isabelle GAUDIN 22 years experience in Clinical Research
COMMERCIAL APIs. S. No Molecule Name Therapeutic Category USDMF EDMF CEP IH
1 Abacavir Sulphate Antiretroviral - * - 2 Abiraterone Acetate Oncology - - - 3 Albendazole Anti-infective - - - 4 Albuterol Sulphate Respiratory - - 5 Alendronate Sodium Trihydrate Metabolic Disorder
The Medical Letter. on Drugs and Therapeutics
The Medical Letter publications are protected by US and international copyright laws. Forwarding, copying or any other distribution of this material is strictly prohibited. For further information call:
FREEDOM OF INFORMATION SOUTH EAST SCOTLAND CANCER NETWORK
Dear Date 06/02/09 Your Ref Our Ref RM/1220 Enquiries to Richard Mutch Extension 89441 Direct Line 0131-536-9441 Direct Fax 0131-536-9009 Email richard.mutch@lhnhslothian.scot.nhs.uk FREEDOM OF INFORMATION
Nexavar. Nexavar (sorafenib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.60 Section: Prescription Drugs Effective Date: July 1,2017 Subject: Nexavar Page: 1 of 5 Last Review
April 2015 May SMC RECOMMENDED MEDICINES FOR USE Recommended for use within NHS Scotland April 2015 May 2015 Date SMC SMC Drug Name
April 2015 May 2015 RECOMMENDED MEDICINES FOR USE Recommended for use within NHS Scotland April 2015 May 2015 Date Advice Published aclidinium / formoterol fumarate dehydrate (Duaklir Genuair) Almirall